“Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis”, J of Skin, vol. 1, no. 3.1, p. s12, Oct. 2017, doi: 10.25251/skin.1.supp.11.